Amneal Reports Q2 2026 Net Revenue of $796 Million
Amneal Pharmaceuticals reported strong second-quarter performance with net revenue of $796 million and raised its full-year 2026 guidance. The company also announced a successful debt repricing to lower interest costs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day